triple-hormone-receptor agonist retatrutide for obesity triple hormone receptor A review of an investigational drug retatrutide, a novel agent the treatment of Triple hormone receptor agonist retatrutide

Dong Rak Kwon and GI Young Park, Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model, Annals of Clinical and Laboratory Science, Volume 45, July-August 2015

It was not reported in the Phase 2 trial

It is a long-acting drug designed for weekly injection, and attempting to split the single-use pen doses by disassembling or transferring medication can carry a high risk of contamination

As of 2026, the investigational drug Retatrutide remains in the advanced stages of clinical development, specifically within its comprehensive Phase 3 TRIUMPH program

It does not prove anything in isolation

AOD-9604 vs Tesamorelin: Head-to-Head Comparison Table The fastest way to compare AOD-9604 and Tesamorelin is side by side: one is a targeted fat-metabolism fragment with an unproven efficacy record, the other is a GH-axis stimulator with a specific FDA-approved indication